### Highlights of This Issue 1151

#### REVIEW

1153  **The Potential Role of miR-451 in Cancer Diagnosis, Prognosis, and Therapy**
Xuan Pan, Rui Wang, and Zhao-Xia Wang

---

#### CHEMICAL THERAPEUTICS

1163  **CXCR4-Targeted Therapy Inhibits VEGF Expression and Chondrosarcoma Angiogenesis and Metastasis**
Xiaojuan Sun, Cherie Charbonneau, Lei Wei, Wentian Yang, Qian Chen, and Richard M. Terek

1171  **CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma**

1180  **Identification and Characterization of a Small-Molecule Inhibitor of Wnt Signaling in Glioblastoma Cells**
Alessandra De Robertis, Silvia Valensin, Marco Rossi, Patrizia Tunicci, Margherita Verani, Antonella De Rosa, Cinzia Giordano, Maurizio Varrone, Arianna Nencini, Carmela Fratelli, Tiziana Benichi, Annette Bakker, Jeffrey Hill, Kanda Sangthongpitag, Vishal Pendihrkara, Boping Liu, Fui Mee Ng, Siew Wen Then, Shi Jing Tai, Seong-Moon Cheong, Xi He, Andrea Caricasole, and Massimiliano Salerno

---

#### LARGE MOLECULE THERAPEUTICS

1202  **MPT0B098, a Novel Microtubule Inhibitor That Destabilizes the Hypoxia-Inducible Factor-1α mRNA through Decreasing Nuclear-Cytoplasmic Translocation of RNA-Binding Protein HuR**

1213  **IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy**
Charles Ferté, Yohann Loriot, Céline Clémenson, Frederic Comm, Andrea Gombos, Jean-Emmanuel Bibault, Ingrid Fumagalli, Saad Hamama, Nathalie Auger, Benoit Lahon, Cyrus Chargari, Julien Calderaro, Jean-Charles Soria, and Eric Deutsch

1223  **Human Anti-Macrophage Migration Inhibitory Factor Antibodies Inhibit Growth of Human Prostate Cancer Cells In Vitro and In Vivo**
Filza Hussain, Michael Freissmuth, Dirk Volkel, Michael Thiele, Patrice Douillard, Gerhard Antoine, Patrick Thurner, Hartmut Ehrlich, Hans-Peter Schwarz, Friedrich Scheiflinger, and Randolph J. Kerschbaumer

1235  **Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2-Induced Apoptosis**
Jeffery S. Swers, Luba Grinberg, Lin Wang, Hui Feng, Kristen Lekstrom, Rosa Carrasco, Zhan Xiao, Ivan Inigo, Ching Ching Leow, Herren Wu, David A. Tice, and Manuel Baca

1245  **Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer**
Kilian M. Gust, David J. McConkey, Shannon Awrey, Paul K. Hegarty, Jing Qing, Jolanta Bondaruk, Avi Ashkenazi, Bogdan Czerniak, Colin P. Dinney, and Peter C. Black
DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Triptolide Induces the Expression of miR-142-3p: A Negative Regulator of Heat Shock Protein 70 and Pancreatic Cancer Cell Proliferation

Resveratrol Induces Differentiation Markers Expression in Anaplastic Thyroid Carcinoma via Activation of Notch1 Signaling and Suppresses Cell Growth
Xiao-Min Yu, Renata Jaskula-Sztul, Kamal Ahmed, April D. Harrison, Muthusamy Kunnimalaiyaan, and Herbert Chen

REST Negatively and ISGF3 Positively Regulate the Human STAT1 Gene in Melanoma
James Amalraj, Samuel J. Cutler, Itbsam Ghazawi, Glen M. Boyle, and Stephen J. Ralph

Drug Repurposing for Gastrointestinal Stromal Tumor
Ziyan Y. Pessetto, Scott J. Weir, Geetika Sethi, Melinda A. Broward, and Andrew K. Godwin

Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells
Carolyne Bardeleben, Sanjai Sharma, Joseph R. Reeve, Sara Bassilian, Patrick Frost, Bao Hoang, Yijiang Shi, and Alan Lichtenstein

Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
Lotfi Abou-Elkacem, Susanne Arns, Gunnar Brix, Felix Gremse, Dieter Zopf, Fabian Kiessling, and Wiltrud Lederle

Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
Matteo S. Carlino, Kavitha Gowrishankar, Catherine A.B. Saunders, Giulietta M. Pupo, Stephanie Snyman, Xu Dong Zhang, Robyn Saw, Therese M. Becker, Richard F. Kefford, Georgina V. Long, and Helen Rizos

Overlapping Functions of ABC Transporters in Topotecan Disposition as Determined in Gene Knockout Mouse Models
Amit K. Tiwari, Rong Zhang, and James M. Gallo

Zoledronic Acid Reverses the Epithelial–Mesenchymal Transition and Inhibits Self-Renewal of Breast Cancer Cells through Inactivation of NF-κB
Amanda J. Schech, Armina A. Kazi, Rabia A. Gilani, and Angela H. Brodie

Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary
Takeshi Hisamatsu, Seiji Mabuchi, Yuri Matsumoto, Mahiru Kawano, Tomoyuki Sasano, Ryoko Takahashi, Kenjiro Sawada, Kimihiko Ito, Hirohisa Kurachi, Russell J. Schilder, Joseph R. Testa, and Tadashi Kimura

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org
Hypoxia can drive loss of tumor cell differentiation and elevate metastatic potential in pancreatic cancer. Inhibition of heparanase with PG545 reduced vascular function and increased hypoxia in a GEMM of pancreatic cancer; however, PG545 treatment did not enhance tumor cell EMT. Immunofluorescence was used to show that tumors from PG545-treated animals express elevated levels of membrane-associated β-catenin, a characteristic of epithelial cells. These data are consistent with observed changes in E-cadherin and other EMT-associated proteins and suggest that the proinvasive effects of hypoxia can be abrogated by inhibition of heparanase. For details, see article by Ostapoff and colleagues on page 1190.